Why the study?
Does peritoneal dialysis reduce circulating inflammatory cytokine levels in patients with refractory congestive heart failure?
Does peritoneal dialysis reduce circulating inflammatory cytokine levels in patients with refractory congestive heart failure?
Peritoneal dialysis in patients with refractory congestive heart failure significantly reduces fluid overload and circulating levels of proinflammatory cytokines like IL-6 and TNF-α.
May support peritoneal dialysis for inflammation in refractory HF; hypothesis-generating and requires randomized confirmation.
Proinflammatory cytokines play a pathogenic role in congestive heart failure. In this study, the effect of peritoneal dialysis treatment on inflammatory cytokines levels in refractory congestive heart failure patients was investigated. During the treatment, the patients reached a well-tolerated edema-free state and demonstrated significant improvement in NYHA functional class. Brain natriuretic peptide decreased significantly after 3 months of treatment and remained stable at 6 months. C-reactive protein, a plasma marker of inflammation, decreased significantly following the treatment. Circulating inflammatory cytokines TNF-α and IL-6 decreased significantly after 3 months of peritoneal dialysis treatment and remained low at 6 months. The reduction in circulating inflammatory cytokines levels may be partly responsible for the efficacy of peritoneal dialysis for refractory congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Kunin et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: